Cargando…

Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?

To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecul...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollein Waldetoft, Kristofer, Gurney, James, Lachance, Joseph, Hoskisson, Paul A., Brown, Sam P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935861/
https://www.ncbi.nlm.nih.gov/pubmed/31874919
http://dx.doi.org/10.1128/mBio.02946-19
_version_ 1783483648544079872
author Wollein Waldetoft, Kristofer
Gurney, James
Lachance, Joseph
Hoskisson, Paul A.
Brown, Sam P.
author_facet Wollein Waldetoft, Kristofer
Gurney, James
Lachance, Joseph
Hoskisson, Paul A.
Brown, Sam P.
author_sort Wollein Waldetoft, Kristofer
collection PubMed
description To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets—have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in Actinobacteria in particular, we propose methodology for evolving antibiotics to circumvent mechanisms of resistance. This exploits the ability of evolution to find solutions to complex problems without a need for design. We review evolutionary theory critical to this approach and argue that it is feasible and has important advantages over current methods for antibiotic discovery.
format Online
Article
Text
id pubmed-6935861
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-69358612020-01-03 Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development? Wollein Waldetoft, Kristofer Gurney, James Lachance, Joseph Hoskisson, Paul A. Brown, Sam P. mBio Opinion/Hypothesis To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics—combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets—have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in Actinobacteria in particular, we propose methodology for evolving antibiotics to circumvent mechanisms of resistance. This exploits the ability of evolution to find solutions to complex problems without a need for design. We review evolutionary theory critical to this approach and argue that it is feasible and has important advantages over current methods for antibiotic discovery. American Society for Microbiology 2019-12-24 /pmc/articles/PMC6935861/ /pubmed/31874919 http://dx.doi.org/10.1128/mBio.02946-19 Text en Copyright © 2019 Wollein Waldetoft et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Opinion/Hypothesis
Wollein Waldetoft, Kristofer
Gurney, James
Lachance, Joseph
Hoskisson, Paul A.
Brown, Sam P.
Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
title Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
title_full Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
title_fullStr Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
title_full_unstemmed Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
title_short Evolving Antibiotics against Resistance: a Potential Platform for Natural Product Development?
title_sort evolving antibiotics against resistance: a potential platform for natural product development?
topic Opinion/Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935861/
https://www.ncbi.nlm.nih.gov/pubmed/31874919
http://dx.doi.org/10.1128/mBio.02946-19
work_keys_str_mv AT wolleinwaldetoftkristofer evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment
AT gurneyjames evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment
AT lachancejoseph evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment
AT hoskissonpaula evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment
AT brownsamp evolvingantibioticsagainstresistanceapotentialplatformfornaturalproductdevelopment